隆回| 古丈| 嘉鱼| 泰宁| 曲江| 疏附| 邳州| 兰溪| 礼泉| 洪洞| 台安| 会东| 师宗| 新荣| 高县| 汨罗| 乾县| 武陟| 肇庆| 陈仓| 东港| 恭城| 盂县| 谢通门| 白碱滩| 镇平| 辽宁| 阳谷| 灌云| 宁阳| 武汉| 澳门| 安庆| 阿勒泰| 吉木乃| 宿松| 平利| 商丘| 肃宁| 陆良| 额尔古纳| 克拉玛依| 沙坪坝| 辽阳县| 藁城| 苏尼特左旗| 达日| 黔江| 张家川| 林芝镇| 兴文| 北碚| 两当| 武进| 曲阳| 张北| 望城| 铁山| 蒲县| 洪洞| 班戈| 沙湾| 馆陶| 五家渠| 邳州| 砀山| 明光| 宜都| 敦化| 黄岩| 蓝山| 宁安| 龙井| 揭阳| 华池| 富裕| 察哈尔右翼中旗| 泗洪| 庐江| 方正| 公主岭| 朝阳市| 宝鸡| 平陆| 福山| 临海| 遂溪| 浙江| 本溪市| 吉首| 福山| 扶余| 城固| 修武| 南平| 凤冈| 修武| 龙井| 子洲| 奎屯| 香港| 进贤| 沙湾| 湘阴| 沅江| 召陵| 漳县| 雁山| 土默特右旗| 富锦| 元谋| 宿豫| 龙陵| 长沙| 仙桃| 华安| 万盛| 达州| 十堰| 赤壁| 临夏县| 汾阳| 宁国| 东莞| 桦甸| 户县| 峨眉山| 贵德| 肥西| 永泰| 东宁| 丹寨| 桃江| 民丰| 云安| 淮阳| 屯留| 常熟| 黄陂| 梅州| 商南| 随州| 铜川| 新竹县| 察哈尔右翼前旗| 沙圪堵| 孙吴| 乃东| 夹江| 本溪市| 中宁| 柳州| 鹰手营子矿区| 西平| 黄陵| 通河| 都江堰| 邵武| 咸宁| 长子| 敖汉旗| 剑河| 莱阳| 栖霞| 滦南| 贵德| 中宁| 双江| 濠江| 阿克陶| 永定| 泸西| 漳州| 建平| 南丹| 猇亭| 博野| 涪陵| 江门| 滦南| 梨树| 金山| 丰润| 安徽| 永川| 商都| 锦州| 巴彦淖尔| 大渡口| 望江| 凤庆| 三门峡| 黄岛| 泗洪| 云霄| 博白| 方山| 红河| 呼玛| 高阳| 从化| 云梦| 石阡| 靖宇| 长白山| 昌平| 泗阳| 徽县| 新都| 鹤壁| 汝州| 云溪| 灌阳| 开阳| 盘县| 宿迁| 商南| 上杭| 麦盖提| 马山| 涞水| 甘洛| 宣恩| 盘山| 澄城| 石狮| 大厂| 苏尼特右旗| 衢州| 扎鲁特旗| 普洱| 宜都| 安乡| 浮梁| 根河| 大姚| 常宁| 安溪| 兴仁| 上虞| 平乡| 尖扎| 都昌| 威宁| 黄山市| 肇州| 罗山| 英德| 怀柔| 米脂| 天峻| 永兴| 紫金| 崇左| 苍山| 舟曲| 宝丰| 盐池| 庆云| 集安| 察哈尔右翼中旗| 衡阳县| 新河| 达州| 百度

清 乾隆版杨柳青年画《金玉满堂》

2019-06-21 08:24 来源:新快报

  清 乾隆版杨柳青年画《金玉满堂》

  百度广大干部群众表示,这一选举结果充分反映了全党全军全国各族人民的共同愿望和心声,充分体现了党的意志、人民意志、国家意志的高度统一,必将鼓舞和激励亿万人民更加紧密团结在以习近平同志为核心的党中央周围,同心同德、开拓进取,为决胜全面建成小康社会、夺取新时代中国特色社会主义伟大胜利、实现中华民族伟大复兴的中国梦而努力奋斗!这是历史和人民作出的郑重选择——党的十八大以来的历史性成就、历史性变革充分表明,习近平总书记是当之无愧的党的核心、军队统帅、人民领袖如潮的掌声,见证着历史。另外,是拧成“一股绳”。

把人民放在心中最高的位置,这是铿锵的宣示,更是坚定的行动。这个专题座谈会,也可以也可以提升我们机关干部的自身能力。

  全国人大、全国政协、中共中央统战部、民盟中央、中共北京市委统战部、民盟北京市委、北京师范大学、《群言》杂志社等单位代表,陶大镛亲属及生前友好90余人参加座谈会。”“抓落实一定要按着葫芦抠籽,真抓实干、步步为营。

  “此次修改宪法,有利于党和国家事业兴旺发达、长治久安,可以让中国‘复兴号’这艘巨轮航向始终正确。”台盟中央主席苏辉表示,五年来台盟持续开展与台湾各界朋友的交流、举办具有台盟特色的品牌活动、鼓励台湾同胞参与祖国建设,不断为两岸关系发展大势汇聚合力。

汪洋强调,宪法修正案充实完善了爱国统一战线和民族关系的内容,有利于铸牢中华民族共同体意识,加强各民族交往交流交融。

  (记者范俊生)

  要更加自觉地联系和服务群众,深入开展协商议政和民主监督,多做凝聚人心、汇聚力量的工作,大兴调查研究之风,更好发挥党委、政府联系群众的桥梁纽带作用。目录序言第一章总纲第二章公民的基本权利和义务第三章国家机构第一节全国人民代表大会第二节中华人民共和国主席第三节国务院第四节中央军事委员会第五节地方各级人民代表大会和地方各级人民政府第六节民族自治地方的自治机关第七节监察委员会第八节人民法院和人民检察院第四章国旗、国歌、国徽、首都序言中国是世界上历史最悠久的国家之一。

  中国共产党领导的多党合作和政治协商制度,既强调中国共产党的领导,也强调发扬社会主义民主。

  同时抓住有利时机,大力推进网格化管理、基层基础、意识形态、宗教和谐等治本之策,把事关根本性、基础性、长远性的工作做起来。新当选的全国政协主席、副主席平均年龄为64岁。

  她说,中共十九大对今后一个时期对台工作作出了重要部署,为做好新时代对台工作提供了根本遵循。

  百度铭记这一时刻,开启壮阔篇章。

  迈向澳门‘一国两制’实践新征程——纪念澳门基本法颁布25周年学术研讨会”22日在澳门旅游塔会展中心举行。全国政协副主席何厚铧出席研讨会开幕式。

  百度 百度 百度

  清 乾隆版杨柳青年画《金玉满堂》

 
责编:

清 乾隆版杨柳青年画《金玉满堂》

Source: Xinhua| 2019-06-21 17:20:33|Editor: Yamei
Video PlayerClose
百度 习近平希望各民主党派和无党派人士要做中国共产党的好参谋、好帮手、好同事,增强责任和担当,共同把中国的事情办好。

Xinhua Headlines: Chinese Nobel laureate's team resolves artemisinin resistance in malaria treatment

Chinese Nobel laureate Tu Youyou receives an interview with Xinhua at home in Beijing, capital of China, June 12, 2019. (Xinhua/Zhou Ning)

BEIJING, June 17 (Xinhua) -- Chinese Nobel laureate Tu Youyou announced Monday that her team has proposed solutions to the problem of artemisinin resistance, providing new evidence that artemisinin is still "the best weapon" against malaria, the world's No. 1 insect-borne infectious disease.

As the winner of the 2015 Nobel Prize for the discovery of artemisinin, Tu said that the drug resistance has remained a big challenge to fighting malaria.

Tu's team has been devoted to the study of the resistant mechanism since 2015 and discovered that partial artemisinin resistance is actually a delay in the clearance of malaria parasites from the bloodstream following treatment with combination therapy.

The 89-year-old scientist explained that plasmodia can enter a state of dormancy during the three-day Artemisinin Combination Treatment (ACT), while they also develop a resistance to partner drugs. But if the treatment period is extended to five to seven days and the partner drugs are replaced, the artemisinin resistance can be solved and plasmodia can be killed.

A paper on the study was published on the April issue of the New England Journal of Medicine (NEJM).

Pedro L. Alonso, director of the Global Malaria Programme of the World Health Organization (WHO), said the article published by Tu and her colleagues on NEJM, a top peer-reviewed journal, has demonstrated the excellence of her research ability. Billions of malaria cases have been treated through artemisinin-based combination therapies.

Artemisinin and its derivatives are known for their ability to swiftly reduce the number of parasites in the blood of patients with malaria and have saved millions of lives worldwide. WHO recommends ACTs as the first and second line treatment for malaria, which inflicts over 400,000 deaths every year worldwide.

The artemisinin resistance was formerly verified in the Greater Mekong river basins.

Tu said that treatment failures with ACTs are often directly attributed to the partner drug, which can be addressed by replacing the partner drug. For example, mefloquine plus artesunate can be switched to DHA with piperaquine if the former fails to deliver positive results.

Artemisinin substances are extracted from Qinghao, a kind of Chinese medicinal herb which has been used for more than 2,000 years in China for treating infectious diseases.

Since 2017, no malaria cases have been reported in China, indicating that the epidemic has been eradicated in the country. China has continued to carry out research on malaria control and prevention and develop artemisinin-based antimalarial drugs for the fight against the disease globally.

"Global malaria control is in line with the thrust of the Chinese government's initiative to build a community with a shared future for humanity," said Alonso. "The antimalarial research work carried out by Tu Youyou's team is groundbreaking, outstanding and immeasurable."

During the past three years of research, Tu's team has found that Artemisinins are also highly effective in treating Lupus Erythematous. Collaborating with 15 institutes nationwide, her team started clinical trials of the treatment in May 2018.

So far, 14 out of 500 applied domestic and foreign volunteer patients have been treated with the therapy. No unanticipated negative effects occurred. The three-phase trials will continue with an appraisal for China's official approval of the therapy to be expected around 2026.

Tu's Artemisinins-based research has helped draw more international attention to Traditional Chinese Medicine (TCM). Oxford University has invited Tu to add a chapter to the Oxford Medical Textbook (6th Edition).

The 6,000-word chapter entitled "Traditional Medicine Exemplified by Traditional Chinese Medicine" has been finalized. It is divided into four parts, explaining TCM, Artemisinin and other TCM's discovery history, their mechanisms and clinical applications. In April, Oxford University Press, the publisher, began proofreading the book.

Professor Timothy M. Cox, the editor of the Oxford Textbook of Medicine, said Tu Youyou's team has accomplished the work of integrating traditional Chinese and Western medicine. The chapter on TCM is important and in-depth so the world medical community can have a deep understanding of TCM.

Currently, the main challenge of TCM lies in the differences of evidence-based medicine, prohibiting TCM drugs including Artemisinins to enter the world's mainstream pharmaceutical markets. "All scientific research must be supported by solid data, evidence and well-designed protocols in order to comply with international medical standards and be accepted by the international community," said Alonso.

Although Chinese antimalarial drugs are highly effective and popular in African countries, the WHO spends a significant amount of its annual government procurement antimalarial funding mainly on foreign rather than Chinese pharmaceutical companies.

Xie Zheng, a technical officer of the WHO, said the production lines of Chinese pharmaceutical enterprises do not meet the WHO GMP technical standards and are difficult to obtain pre-qualification. They can only commission foreign pharmaceutical enterprises that meet the standards or go abroad in the way of government procurement.

China has made it a national strategy to encourage evidence-based medicine research and GMP standard construction so pharmaceutical enterprises can speed up the transformation of their production lines to obtain WHO certification and approval, said Liao Fulong, a senior researcher with Tu's team.

(Video reporters: Wang Junlu, Zhou Ning, Luo Guojun, Gai Boming; Video editor: Liu Xiaorui)

   1 2 Next  

KEY WORDS:
EXPLORE XINHUANET
010020070750000000000000011103261381506051
百度